Laboratorios Farmaceuticos Rovi, S.A. ROVI
BME · Spain · Health Technology
€57.40+0.05 (+0.09%)
Market open· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Laboratorios Farmaceuticos Rovi SA (WBO:ROVI) reports strong revenue growth and strategic acquisitions, while navigating pricing pressures and increased expenses.
As global markets navigate a landscape marked by heightened inflation concerns and geopolitical tensions, major indices like the Dow Jones Industrial Average and S&P 500 have reached new heights, driven in part by enthusiasm for AI-related stocks. Amid this complex environment, small-cap and value stocks have shown resilience, outperforming their larger counterparts. In such a setting, identifying undervalued stocks becomes crucial for investors looking to capitalize on potential market...
Despite a dip in operating revenues, Rovi SA showcases resilience with strong gross profit growth and strategic expansion in the U.S. market.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.